Literature DB >> 12526087

Statin inhibits interferon-gamma-induced expression of intercellular adhesion molecule-1 (ICAM-1) in vascular endothelial and smooth muscle cells.

Hyo Kyun Chung1, In Kyu Lee, Hyokyung Kang, Jae Mi Suh, Ho Kim, Ki Cheol Park, Dong Wook Kim, Young Kun Kim, Heung Kyu Ro, Minho Shong.   

Abstract

Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, known as statins, are widely used for primary and secondary prevention of coronary artery atherosclerosis. Pathogenesis of atherosclerosis is multistep processes where transendothelial migration of various leukocytes including monocytes is a crucial step. Interferon-gamma (IFN-gamma) contributes in this process by activating macrophages and T-lymphocytes, and by inducing adhesion molecules in vascular endothelial and smooth muscle cells. In this study we investigated the expression of intercellular cell adhesion molecule-1 (ICAM-1) in transformed endothelial cell line ECV304 cells as influenced by lovastatin, tumor necrosis factor-alpha (TNF-alpha) and IFN-gamma. Results show that lovastatin suppresses expression of ICAM-1 by inhibiting the IFN-gamma-induced extracellular signal-regulated kinase (ERK) p44/p42-STAT1 signaling pathway. In cells treated with lovastatin and IFN-gamma, ICAM-1 was expressed at a lower level than in cells treated with IFN-gamma alone. However, lovastatin does not reduce TNF-alpha induced expression of ICAM-1. A similar result was observed in cells treated with the MEKK inhibitor PD98059 and IFN-gamma. Cis-acting DNA sequence elements were identified in the 5'-flanking region of the ICAM-1 promoter that mediate inhibition by lovastatin; these sequences map to the IFN-gamma activated site which also binds the STAT1 homodimer. However, lovastatin did not inhibit IFN-gamma-mediated induction of the Y701 phosphorylated form of STAT1. But lovastatin does inhibit the IFN-gamma-mediated phosphorylation of ERK1/ERK2 (T202/Y204) and S727 phosphorylation of STAT1. TNF-alpha does not induce phosphorylation of ERK1/ERK2 and S727 in ECV304 and smooth muscle cells. The results provide the evidences that statins may have beneficial effects by inhibiting IFN-gamma action in atherosclerotic process

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12526087     DOI: 10.1038/emm.2002.63

Source DB:  PubMed          Journal:  Exp Mol Med        ISSN: 1226-3613            Impact factor:   8.718


  20 in total

Review 1.  Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention.

Authors:  Maureen McMahon; Bevra H Hahn; Brian J Skaggs
Journal:  Expert Rev Clin Immunol       Date:  2011-03       Impact factor: 4.473

Review 2.  Efficacy of short-term high-dose atorvastatin pretreatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a meta-analysis of nine randomized controlled trials.

Authors:  Yangchun Liu; Qiang Su; Lang Li
Journal:  Clin Cardiol       Date:  2013-08-27       Impact factor: 2.882

Review 3.  Statins--treatment option for central nervous system autoimmune disease?

Authors:  Martin S Weber; Lawrence Steinman; Scott S Zamvil
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

Review 4.  Statin treatment for patients with heart failure.

Authors:  W H Wilson Tang; Gary S Francis
Journal:  Nat Rev Cardiol       Date:  2010-03-16       Impact factor: 32.419

Review 5.  Utility of statin therapy using high-sensitivity C-reactive protein as an indicator of coronary heart disease risk.

Authors:  Vijay Nambi; Christie M Ballantyne
Journal:  Curr Atheroscler Rep       Date:  2005-02       Impact factor: 5.113

Review 6.  Statin treatment in multiple sclerosis: a systematic review and meta-analysis.

Authors:  Gorm Pihl-Jensen; Anna Tsakiri; Jette Lautrup Frederiksen
Journal:  CNS Drugs       Date:  2015-04       Impact factor: 5.749

Review 7.  Immunological aspects of atherosclerosis.

Authors:  S Garrido-Urbani; M Meguenani; F Montecucco; B A Imhof
Journal:  Semin Immunopathol       Date:  2013-11-09       Impact factor: 9.623

8.  Acute treatment with rosuvastatin protects insulin resistant (C57BL/6J ob/ob) mice against transient cerebral ischemia.

Authors:  Keita Mayanagi; Prasad V Katakam; Tamas Gáspár; Ferenc Domoki; David W Busija
Journal:  J Cereb Blood Flow Metab       Date:  2008-07-30       Impact factor: 6.200

9.  Hypercholesterolemia and microvascular dysfunction: interventional strategies.

Authors:  Phoebe A Stapleton; Adam G Goodwill; Milinda E James; Robert W Brock; Jefferson C Frisbee
Journal:  J Inflamm (Lond)       Date:  2010-11-18       Impact factor: 4.981

10.  Interferon-γ: Promising therapeutic target in atherosclerosis.

Authors:  Joe We Moss; Dipak P Ramji
Journal:  World J Exp Med       Date:  2015-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.